Personalized prediabetes treatment: genetics may predict who benefits from ozempic

NCT ID NCT05119179

Recruiting now Knowledge-focused Sponsor: The University of Texas Health Science Center, Houston Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how genetic differences in Mexican-Americans with prediabetes affect their response to semaglutide (Ozempic), a GLP-1 drug. Researchers will measure changes in insulin production and sensitivity, and analyze gene activity. The goal is to understand why some people respond better than others, which could lead to more personalized treatments for prediabetes and related conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Ozempic)
What this could lead to: If successful, this could lead to personalized treatment plans for prediabetes based on a person's genetic makeup.
What could go wrong: This is an early-stage genetic study, not a treatment trial. Results may not lead to immediate clinical changes, and individual responses vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREDIABETES

Contacts and locations

Locations

UTHealth Clinical Research Unit (CRU) at UT Brownsville
RECRUITING

Brownsville, Texas, 78520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.